{"id":"sb5-adalimumab-biosimilar","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"10-15","effect":"Headache"},{"rate":"2-5","effect":"Serious infections"},{"rate":"<1","effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SB5 is a monoclonal antibody biosimilar that mimics the mechanism of reference adalimumab by binding to soluble and membrane-bound TNF-α, preventing its interaction with TNF receptors on immune cells. This blocks TNF-α-mediated inflammation and is used to treat TNF-driven autoimmune and inflammatory diseases. As a biosimilar, SB5 demonstrates comparable efficacy and safety to the reference product while offering potential cost advantages.","oneSentence":"SB5 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:58.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Hidradenitis suppurativa"}]},"trialDetails":[{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT02167139","phase":"PHASE3","title":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":544}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SB5 (Adalimumab Biosimilar)","genericName":"SB5 (Adalimumab Biosimilar)","companyName":"Samsung Bioepis Co., Ltd.","companyId":"samsung-bioepis-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB5 is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}